|1.||Neyts, J: 2 articles (11/2001 - 03/2000)|
|2.||De Clercq, E: 2 articles (11/2001 - 03/2000)|
|3.||Durham, Stephen K: 1 article (11/2007)|
|4.||Woicke, Jochen: 1 article (11/2007)|
|5.||Mense, Mark G: 1 article (11/2007)|
|6.||Shiota, Hiroshi: 1 article (07/2004)|
|7.||Hu, Nan: 1 article (07/2004)|
|8.||Zhang, Y: 1 article (11/2001)|
|9.||Schols, D: 1 article (11/2001)|
|10.||De Bolle, L: 1 article (11/2001)|
03/01/1996 - "These results suggest that BMS-180194 may be of value as an oral antiviral agent for treatment of opportunistic CMV infections in immunocompromised individuals."
03/01/1996 - "The parenteral or oral antiviral efficacy of BMS-180194 was comparable to that of parenteral ganciclovir against MCMV infection in the present study. "
03/01/1996 - "The antiviral effectiveness of BMS-180194 against murine cytomegalovirus (MCMV) infection in immunocompromised C57BL/6 mice was investigated and was compared to that of ganciclovir (GCV). "
12/01/2000 - "Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection."
03/15/1999 - "Lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyc lobutyl]guanine (LBV) is a novel antiviral agent with activity against ganciclovir-resistant cytomegalovirus (CMV) strains, that is in phase II clinical trials for the treatment of CMV infections. "
|2.||Chronic Hepatitis B
|3.||Cytomegalovirus Infections (Inclusion Disease)
07/01/2004 - "To elucidate the potentiality of emergence of drug-resistance to carbocyclic oxetanocin G (C.OXT-G), a new effective antiviral drug for herpetic keratitis during treatment and the mechanism of this drug resistance. "
05/01/1996 - "A new antiviral compound, carbocyclic oxetanocin G (C.OXT-G) has potent anti-herpes simplex virus activity and high water solubility, so the clinical effect of C.OXT-G eyedrops on ulcerative herpetic keratitis was evaluated. "
|5.||Herpesviridae Infections (Herpesvirus Infection)
07/01/1991 - "The new antiviral nucleoside SQ 34,514 [(1R-1 alpha, 2 beta, 3 alpha)-2-amino-9- [2,3-bis(hydroxymethyl)cyclobutyl]-6H-purin-6-one], the active R isomer of racemic SQ 33,054 (cyclobut-G), was evaluated for efficacy in the treatment of herpesvirus infections in mice. "
11/01/2001 - "They were selected either because they are already approved for clinical use in the treatment of herpesvirus infections (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, brivudin, foscarnet and cidofovir) or have demonstrated marked activity against herpesviruses (lobucavir, H2G, A-5021, D/L-cyclohexenyl G and S2242). "
|8.||dioxolane guanosine (DXG)